The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.

2.50
Hdl Handle:
http://hdl.handle.net/10541/70439
Title:
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.
Authors:
Griffiths, Stephen D; Burthem, John; Unwin, Richard D; Holyoake, Tessa L; Melo, Junia V; Lucas, Guy S; Whetton, Anthony D
Abstract:
Chronic Myeloid Leukemia (CML) is a hematopoietic stem cell disease, associated with a t(9, 22) chromosomal translocation leading to formation of the BCR/ABL chimeric protein, which has an intrinsic tyrosine kinase activity. Recently, the BCR/ABL tyrosine kinase inhibitor imatinib mesylate (imatinib) has been successfully used clinically, although, disease relapse can still occur. The precise detail of the mechanism by which CML cells respond to imatinib is still unclear. We therefore systematically examined the effects of imatinib on the primitive CML cell proteome, having first established that the drug inhibits proliferation and induces increased apoptosis and differentiation. To define imatinib-induced effects on the CML proteome, we employed isobaric tag peptide labeling (iTRAQ) coupled to two-dimensional liquid chromatography/tandem mass spectrometry. Given the limited clinical material available, the isobaric tag approach identified a large population of proteins and provided relative quantification on four samples at once. Novel consequences of the action of imatinib were identified using this mass spectrometric approach. DEAD-box protein 3, heat shock protein 105 kDa, and peroxiredoxin-3 were identified as potential protein markers for response to imatinib.
Affiliation:
Division of Cancer Studies, Faculty of Medical and Human Sciences, Christie Hospital, University of Manchester, Wilmslow Road, Manchester M20 9BX, UK.
Citation:
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. 2007, 36 (2):81-9 Mol. Biotechnol.
Journal:
Molecular Biotechnology
Issue Date:
Jun-2007
URI:
http://hdl.handle.net/10541/70439
DOI:
10.1007/s12033-007-0005-5
PubMed ID:
17914187
Type:
Article
Language:
en
ISSN:
1073-6085
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGriffiths, Stephen D-
dc.contributor.authorBurthem, John-
dc.contributor.authorUnwin, Richard D-
dc.contributor.authorHolyoake, Tessa L-
dc.contributor.authorMelo, Junia V-
dc.contributor.authorLucas, Guy S-
dc.contributor.authorWhetton, Anthony D-
dc.date.accessioned2009-06-15T11:47:58Z-
dc.date.available2009-06-15T11:47:58Z-
dc.date.issued2007-06-
dc.identifier.citationThe use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. 2007, 36 (2):81-9 Mol. Biotechnol.en
dc.identifier.issn1073-6085-
dc.identifier.pmid17914187-
dc.identifier.doi10.1007/s12033-007-0005-5-
dc.identifier.urihttp://hdl.handle.net/10541/70439-
dc.description.abstractChronic Myeloid Leukemia (CML) is a hematopoietic stem cell disease, associated with a t(9, 22) chromosomal translocation leading to formation of the BCR/ABL chimeric protein, which has an intrinsic tyrosine kinase activity. Recently, the BCR/ABL tyrosine kinase inhibitor imatinib mesylate (imatinib) has been successfully used clinically, although, disease relapse can still occur. The precise detail of the mechanism by which CML cells respond to imatinib is still unclear. We therefore systematically examined the effects of imatinib on the primitive CML cell proteome, having first established that the drug inhibits proliferation and induces increased apoptosis and differentiation. To define imatinib-induced effects on the CML proteome, we employed isobaric tag peptide labeling (iTRAQ) coupled to two-dimensional liquid chromatography/tandem mass spectrometry. Given the limited clinical material available, the isobaric tag approach identified a large population of proteins and provided relative quantification on four samples at once. Novel consequences of the action of imatinib were identified using this mass spectrometric approach. DEAD-box protein 3, heat shock protein 105 kDa, and peroxiredoxin-3 were identified as potential protein markers for response to imatinib.en
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subjectTumour Cellsen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshApoptosis-
dc.subject.meshCell Differentiation-
dc.subject.meshCell Proliferation-
dc.subject.meshChromatography, Liquid-
dc.subject.meshDEAD-box RNA Helicases-
dc.subject.meshHSP110 Heat-Shock Proteins-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive-
dc.subject.meshPeptides-
dc.subject.meshPeroxidases-
dc.subject.meshPeroxiredoxins-
dc.subject.meshPiperazines-
dc.subject.meshProtein Kinase Inhibitors-
dc.subject.meshProteome-
dc.subject.meshProteomics-
dc.subject.meshPyrimidines-
dc.subject.meshTandem Mass Spectrometry-
dc.subject.meshTumor Cells, Cultured-
dc.titleThe use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.en
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Studies, Faculty of Medical and Human Sciences, Christie Hospital, University of Manchester, Wilmslow Road, Manchester M20 9BX, UK.en
dc.identifier.journalMolecular Biotechnologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.